Elicio Therapeutics is developing the Irvine Lab’s lymph node targeting vaccine technology to fight COVID-19. With promising preclinical evidence of increased T cell and antibody response against coronavirus proteins, the company hopes to accelerate clinical translation using insight gained from their already-completed manufacturing and toxicology studies in KRAS-driven cancers.